5-fluorouracil poisoning

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:217064T45.1
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

5-Fluorouracil (5-FU) poisoning, also known as 5-fluorouracil toxicity, refers to severe and potentially life-threatening adverse reactions to the chemotherapy drug 5-fluorouracil or its oral prodrug capecitabine. 5-Fluorouracil is widely used in the treatment of solid tumors including colorectal, breast, head and neck, and gastrointestinal cancers. Toxicity occurs when the drug accumulates to dangerous levels in the body, most commonly due to a deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene. DPD is responsible for metabolizing over 80% of administered 5-FU, and patients with partial or complete DPD deficiency are at significantly increased risk of severe poisoning even at standard therapeutic doses. The condition affects multiple body systems. Hematologic toxicity manifests as severe neutropenia, leukopenia, thrombocytopenia, and pancytopenia, which can lead to life-threatening infections and bleeding. Gastrointestinal effects include severe mucositis, stomatitis, intractable diarrhea, nausea, and vomiting. Neurological toxicity can present as cerebellar ataxia, encephalopathy, confusion, and altered consciousness. Cardiac toxicity, including chest pain, arrhythmias, and cardiomyopathy, may also occur. Dermatologic manifestations such as hand-foot syndrome and severe dermatitis are common. In the most severe cases, multi-organ failure and death can result. Treatment of 5-FU poisoning includes immediate discontinuation of the drug and supportive care. Uridine triacetate (Vistogard) is an FDA-approved antidote that, when administered within 96 hours of the last dose of 5-FU or capecitabine, can significantly reduce mortality by competitively inhibiting the incorporation of toxic 5-FU metabolites into RNA. Preventive pharmacogenomic testing for DPYD variants before initiating 5-FU-based chemotherapy is increasingly recommended by clinical guidelines to identify at-risk patients and adjust dosing accordingly.

Also known as:

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for 5-fluorouracil poisoning.

View clinical trials →

No actively recruiting trials found for 5-fluorouracil poisoning at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the 5-fluorouracil poisoning community →

Specialists

1 foundView all specialists →
VP
Vibeke B Hansen, MD, PhD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to 5-fluorouracil poisoning.

Search all travel grants →NORD Financial Assistance ↗

Community

Open 5-fluorouracil poisoningForum →

No community posts yet. Be the first to share your experience with 5-fluorouracil poisoning.

Start the conversation →

Latest news about 5-fluorouracil poisoning

No recent news articles for 5-fluorouracil poisoning.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about 5-fluorouracil poisoning

What is 5-fluorouracil poisoning?

5-Fluorouracil (5-FU) poisoning, also known as 5-fluorouracil toxicity, refers to severe and potentially life-threatening adverse reactions to the chemotherapy drug 5-fluorouracil or its oral prodrug capecitabine. 5-Fluorouracil is widely used in the treatment of solid tumors including colorectal, breast, head and neck, and gastrointestinal cancers. Toxicity occurs when the drug accumulates to dangerous levels in the body, most commonly due to a deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene. DPD is responsible for metabolizing over 80% of administered

How is 5-fluorouracil poisoning inherited?

5-fluorouracil poisoning follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does 5-fluorouracil poisoning typically begin?

Typical onset of 5-fluorouracil poisoning is adult. Age of onset can vary across affected individuals.

Which specialists treat 5-fluorouracil poisoning?

1 specialists and care centers treating 5-fluorouracil poisoning are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.